Elevated triglyceride levels tied to compromised kidney function

They addressed the importance of renal function monitoring in these patients.

In the present study, researchers investigated the role of hypertriglyceridemia on renal function decline and the development of end-stage kidney disease (ESKD) in a real-world clinical setting.

They used databases of 3 Italian Local Health Units for the study. They measured outcomes as a reduction in eGFR) ≥30%.

The key Results of the study are:

• The study included 45,000 subjects.
• Thirty-nine thousand nine hundred thirty-five had normal-TGs.
• Five thousand twenty-nine participants had high triglycerides or HTG.
• Thirty-six participants had very high TG.
• The baseline eGFR was 96.0 ± 66.4 mL/min.
• In normal-TG, HTG and vHTG subjects, the incidence of eGFR reduction was 27.1, 31.1 and 35.1 per 1000 person-years.
• In normal-TG and HTG/vHTG subjects, the incidence of ESKD was 0.7 and 0.9 per 1000 person-years, respectively.
• HTG subjects had a risk of eGFR reduction or ESKD occurrence by 48% compared to normal-TG subjects.
• Each 50 mg/dL increase in TG levels increased the risk of eGFR reduction and ESKD.

Concluding further, they explained, based on results from this real-world data, a moderate-to-severe increase in plasma TG levels causes deterioration of long-term kidney function.

They said the large sample size and length of follow-up allowed us to capture sufficient insights, which is the strength of our study.

They acknowledged Alfasigma (Italy) purchased the study report that is the basis for this article.

Further reading:

https://www.ejinme.com/article/S0953-6205(23)00059-6/fulltext